Do analysts rate FNCH or MBRX?

Moleculin Biotech has a consensus price target of $22.00, suggesting a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation & earnings, FNCH or MBRX?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A

Is FNCH or MBRX more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Moleculin Biotech N/A -1,422.36% -70.62%

Does the media refer more to FNCH or MBRX?

In the previous week, Moleculin Biotech had 5 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 6 mentions for Moleculin Biotech and 1 mentions for Finch Therapeutics Group. Moleculin Biotech's average media sentiment score of 0.78 beat Finch Therapeutics Group's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MBRX or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -63.38% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -1,422.36% -70.62% Kiora Pharmaceuticals N/A -63.38% -44.33%

Does the media prefer MBRX or KPRX?

In the previous week, Moleculin Biotech had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 6 mentions for Moleculin Biotech and 3 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.01 beat Moleculin Biotech's score of 0.78 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiora Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MBRX or INTS?

Intensity Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is MBRX or INTS more profitable?

Intensity Therapeutics' return on equity of -116.61% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -1,422.36% -70.62% Intensity Therapeutics N/A -116.61% -94.01%

Does the media prefer MBRX or INTS?

In the previous week, Intensity Therapeutics had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 7 mentions for Intensity Therapeutics and 6 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.78 beat Intensity Therapeutics' score of -0.02 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate QNRX or MBRX?

Moleculin Biotech has a consensus price target of $22.00, indicating a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings & valuation, QNRX or MBRX?

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A

Is QNRX or MBRX more profitable?

Quoin Pharmaceuticals' return on equity of -489.85% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Quoin Pharmaceuticals N/A -489.85% -221.29% Moleculin Biotech N/A -1,422.36% -70.62%

Does the media favor QNRX or MBRX?

In the previous week, Moleculin Biotech had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 6 mentions for Moleculin Biotech and 3 mentions for Quoin Pharmaceuticals. Moleculin Biotech's average media sentiment score of 0.78 beat Quoin Pharmaceuticals' score of 0.62 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MBRX or PHXM?

Moleculin Biotech presently has a consensus target price of $22.00, indicating a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, MBRX or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is MBRX or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -1,422.36% -70.62% PHAXIAM Therapeutics N/A N/A N/A

Moleculin Biotech (MBRX) Competitors

$0.61 +0.04 (+6.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.62 +0.01 (+2.30%)

As of 07:59 PM Eastern

Compare

MBRX vs. FNCH, KPRX, INTS, QNRX, and PHXM

Should you buy Moleculin Biotech stock or one of its competitors? Moleculin Biotech's main competitors and comparable companies include Finch Therapeutics Group (FNCH), Kiora Pharmaceuticals (KPRX), Intensity Therapeutics (INTS), Quoin Pharmaceuticals (QNRX), and PHAXIAM Therapeutics (PHXM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Moleculin Biotech compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

Moleculin Biotech has a consensus price target of $22.00, suggesting a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Finch Therapeutics Group's return on equity of -69.14% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Moleculin Biotech	N/A	-1,422.36%	-70.62%

In the previous week, Moleculin Biotech had 5 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 6 mentions for Moleculin Biotech and 1 mentions for Finch Therapeutics Group. Moleculin Biotech's average media sentiment score of 0.78 beat Finch Therapeutics Group's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Finch Therapeutics Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Moleculin Biotech beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to Kiora Pharmaceuticals?

Moleculin Biotech (NASDAQ:MBRX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Moleculin Biotech has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.38, suggesting that its stock price is 138% less volatile than the broader market.

Kiora Pharmaceuticals' return on equity of -63.38% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-1,422.36%	-70.62%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

In the previous week, Moleculin Biotech had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 6 mentions for Moleculin Biotech and 3 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.01 beat Moleculin Biotech's score of 0.78 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiora Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 3,506.56%. Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 292.16%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kiora Pharmaceuticals has higher revenue and earnings than Moleculin Biotech. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A

Summary

Moleculin Biotech and Kiora Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Moleculin Biotech compare to Intensity Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Intensity Therapeutics' return on equity of -116.61% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-1,422.36%	-70.62%
Intensity Therapeutics	N/A	-116.61%	-94.01%

In the previous week, Intensity Therapeutics had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 7 mentions for Intensity Therapeutics and 6 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.78 beat Intensity Therapeutics' score of -0.02 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intensity Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

Moleculin Biotech currently has a consensus target price of $22.00, indicating a potential upside of 3,506.56%. Intensity Therapeutics has a consensus target price of $37.50, indicating a potential upside of 846.97%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Moleculin Biotech has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market.

Summary

Intensity Therapeutics beats Moleculin Biotech on 8 of the 12 factors compared between the two stocks.

How does Moleculin Biotech compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 11.2% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Moleculin Biotech has a consensus price target of $22.00, indicating a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

Quoin Pharmaceuticals' return on equity of -489.85% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Moleculin Biotech	N/A	-1,422.36%	-70.62%

In the previous week, Moleculin Biotech had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 6 mentions for Moleculin Biotech and 3 mentions for Quoin Pharmaceuticals. Moleculin Biotech's average media sentiment score of 0.78 beat Quoin Pharmaceuticals' score of 0.62 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quoin Pharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market.

Summary

Moleculin Biotech beats Quoin Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to PHAXIAM Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

PHAXIAM Therapeutics' return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-1,422.36%	-70.62%
PHAXIAM Therapeutics	N/A	N/A	N/A

In the previous week, Moleculin Biotech had 6 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 6 mentions for Moleculin Biotech and 0 mentions for PHAXIAM Therapeutics. Moleculin Biotech's average media sentiment score of 0.78 beat PHAXIAM Therapeutics' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Positive
PHAXIAM Therapeutics	Neutral

Moleculin Biotech presently has a consensus target price of $22.00, indicating a potential upside of 3,506.56%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Moleculin Biotech has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

Summary

Moleculin Biotech beats PHAXIAM Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.06M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.03	640.15	211.09	21.74
Price / Sales	N/A	743.87	602.98	92.99
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.13	11.60	12.91	6.24
Net Income	-$33.56M	$2.77B	$3.45B	$347.60M
7 Day Performance	48.96%	0.17%	1.12%	1.07%
1 Month Performance	-73.01%	0.35%	1.79%	1.03%
1 Year Performance	-96.23%	161.52%	67.69%	20.77%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	2.4919 of 5 stars	$0.61 +6.8%	$22.00 +3,506.6%	-96.6%	$4.06M	N/A	N/A	20	Earnings Report Short Interest Increase Gap Up
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
KPRX Kiora Pharmaceuticals	3.0915 of 5 stars	$2.64 +0.8%	$10.00 +278.8%	+4.0%	$11.59M	$16.02M	N/A	10	Earnings Report Short Interest Decrease
INTS Intensity Therapeutics	3.2964 of 5 stars	$4.16 -1.0%	$37.50 +801.4%	-44.8%	$11.35M	N/A	N/A	2,021	Earnings Report Analyst Forecast Short Interest Decrease
QNRX Quoin Pharmaceuticals	0.7363 of 5 stars	$5.89 +10.1%	N/A	-17.0%	$10.74M	N/A	N/A	4	News Coverage Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. FNCH, KPRX, INTS, QNRX, and PHXM

How does Moleculin Biotech compare to Finch Therapeutics Group?

Summary

How does Moleculin Biotech compare to Kiora Pharmaceuticals?

Summary

How does Moleculin Biotech compare to Intensity Therapeutics?

Summary

How does Moleculin Biotech compare to Quoin Pharmaceuticals?

Summary

How does Moleculin Biotech compare to PHAXIAM Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. FNCH, KPRX, INTS, QNRX, and PHXM

How does Moleculin Biotech compare to Finch Therapeutics Group?

Which has more risk and volatility, FNCH or MBRX?

Which has preferable valuation & earnings, FNCH or MBRX?

Do analysts rate FNCH or MBRX?

Is FNCH or MBRX more profitable?

Does the media refer more to FNCH or MBRX?

Do institutionals & insiders hold more shares of FNCH or MBRX?

Summary

How does Moleculin Biotech compare to Kiora Pharmaceuticals?

Do insiders & institutionals hold more shares of MBRX or KPRX?

Which has more volatility & risk, MBRX or KPRX?

Is MBRX or KPRX more profitable?

Does the media prefer MBRX or KPRX?

Do analysts recommend MBRX or KPRX?

Which has better valuation & earnings, MBRX or KPRX?

Summary

How does Moleculin Biotech compare to Intensity Therapeutics?

Is MBRX or INTS more profitable?

Does the media prefer MBRX or INTS?

Which has preferable valuation & earnings, MBRX or INTS?

Do analysts prefer MBRX or INTS?

Do institutionals & insiders have more ownership in MBRX or INTS?

Which has more volatility and risk, MBRX or INTS?

Summary

How does Moleculin Biotech compare to Quoin Pharmaceuticals?

Do insiders & institutionals have more ownership in QNRX or MBRX?

Do analysts rate QNRX or MBRX?

Which has better earnings & valuation, QNRX or MBRX?

Is QNRX or MBRX more profitable?

Does the media favor QNRX or MBRX?

Which has more volatility and risk, QNRX or MBRX?

Summary

How does Moleculin Biotech compare to PHAXIAM Therapeutics?

Is MBRX or PHXM more profitable?

Does the media refer more to MBRX or PHXM?

Do analysts prefer MBRX or PHXM?

Do insiders and institutionals believe in MBRX or PHXM?

Which has stronger earnings and valuation, MBRX or PHXM?

Which has more risk and volatility, MBRX or PHXM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools